Insights on Innovation, R&D, and IP
Perspectives on patents, scientific research, emerging technologies, and the strategies shaping modern R&D
Michael Devon, a retired Research Fellow who spent 34 years at Dow tested three AI systems against complex, known-answer R&D scenarios. The largest performance gap appeared where technical depth, IP interpretation and roadmap development mattered most.
General-purpose AI tools such as Microsoft Copilot and Claude Opus 5 are built primarily around frontier foundation models and broad-access knowledge. Cypris can use the same class of foundation models, but grounds them in focused scientific and intellectual property datasets connected through domain-specific ontologies.
This comparison was designed to test whether that additional intelligence layer materially changes the quality of technical research.
Michael Devon, a retired Research Fellow who spent 34 years at Dow, evaluated Cypris, Microsoft Copilot and Claude Opus 5 across two technical scenarios and four prompts. He deliberately chose areas he knew intimately, allowing him to distinguish a plausible summary from an analysis that captured the technical realities, historical context and commercial considerations required to build an R&D strategy.
The scenarios were representative of projects that historically required weeks of coordinated researcher effort. The objective was not simply to determine which tool could find relevant information. It was to determine which could transform that information into useful technical and strategic guidance rooted in real world context.
Evaluation design
The comparison covered two technology landscapes: hollow latex particle opacifiers and the use of hydroxypropyl methylcellulose, or HPMC, in osmotic drug-delivery systems. The outputs were evaluated based on result quality, strategic insight, accuracy and the ability to recognize the boundaries between related technologies.
The hollow particle prompts asked the systems to map the competitive and IP landscape, identify emerging participants in Mexico and Asia, detect licensing or corporate activity and locate white space. They were then asked to recommend alternative materials, particle architectures and manufacturing mechanisms that could support a defensible product strategy.
The osmotic delivery prompts asked the systems to identify manufacturers and marketed products, followed by an analysis of HPMC grades, viscosity specifications, processing methods, prior art and potential formulation strategies.
Where the tools diverged
All three tools were capable of producing a credible general summary. The meaningful differences appeared as the work moved from describing the landscape to deciding what to do next.
Devon found that Cypris produced the strongest overall result, with the clearest advantage in the more technically and strategically complex hollow particle scenario. Claude and Copilot generally summarized what had been published. Cypris more frequently identified the specific technical issues, changes in IP ownership, commercial signals and research directions that could influence an actual development program.
Comparative findings at a glance
These distinctions were particularly visible in Devon's analysis of technical implementation, IP transfers, market context and research direction.
Scenario One: Hollow Latex Particle Opacifiers
All three tools passed the baseline test
Each system produced a reasonable summary of the general hollow particle landscape. Devon found no serious factual errors within the information each tool chose to present.
That baseline performance was important, but it did not determine the outcome. The systems differed substantially in the usefulness of their output for technical strategy development, with Cypris holding the clear advantage.
Cypris identified the technical issue most likely to derail a new entrant
One of the most consequential differences involved particle collapse.
Cypris recognized that maintaining particle structure was a central technical challenge and produced a useful explanation of the issue. Claude and Copilot did not identify its importance.
For a researcher, this was not a minor omission. A new entrant that fails to understand or overcome particle collapse could invest considerable time and capital in a manufacturing approach that does not perform under practical conditions. By surfacing the issue, Cypris provided information that could directly alter experimental priorities and development sequencing.
Cypris was not flawless. It did not fully distinguish between Dow's hollow latex work using caustic expansion and a separate abandoned macroporous latex approach. However, Claude and Copilot missed the macroporous work entirely.
The distinction illustrates the difference between partial technical interpretation and simple omission. Cypris found the relevant body of work but needed greater precision in separating the approaches. The general AI tools failed to surface the alternative development path at all.
Cypris produced a stronger picture of the IP landscape
Patent landscapes are often presented as lists of companies, filings and portfolio sizes. For technology strategy, that is rarely sufficient.
Researchers need to understand whether patents remain active and relevant, whether they have been transferred, whether the underlying technology is commercially practiced and whether a seemingly large portfolio contains meaningful gaps.
Claude and Copilot missed technology transfers between companies. Devon also found that Claude failed to recognize that significant portions of the IP landscape had changed hands or become outdated. These omissions can distort the competitive picture by assigning technology to the wrong owner or treating historically important patents as if they still define the current opportunity.
Cypris provided a more useful view of how the IP was structured and where potential white space existed. This helped move the analysis beyond a patent count and toward questions such as:
- Who currently controls the relevant technology?
- Which patents still create meaningful barriers?
- Where has ownership changed?
- Which approaches appear abandoned or underdeveloped?
- Where could a new entrant build, partner or acquire?
Devon noted that all three tools could be improved by incorporating deeper patent-office and file-wrapper information, maintenance status, litigation history and citation patterns. Those signals help determine whether a portfolio is genuinely defensible or simply appears strong based on volume.
Cypris surfaced technical and commercial concepts the others missed
Cypris was the only tool to identify the use of hollow particles in thermal printing. It also suggested additional markets and alternative applications.
That finding demonstrated a broader advantage in state-of-the-art analysis. Cypris did not restrict the output to the most obvious use of hollow particles as opacifiers. It connected the underlying technology to another commercially relevant application that Claude and Copilot failed to identify.
The distinction matters because technical strategy requires answering two different questions:
- Can the organization develop the technology?
- Is the opportunity commercially worth pursuing?
Claude and Copilot largely addressed the first question through general technical summaries. Cypris brought in more of the information required to begin addressing the second.
Some commercial outputs still required scrutiny. Devon considered Cypris' estimated 10 percent compound annual growth rate for the broader hollow particle market questionable, although its approximately 5 percent estimate for the thermal-printing segment appeared reasonable. The advantage was not that every market figure was definitive. It was that Cypris recognized adjacent commercial applications and incorporated them into the strategic analysis at all.
Cypris produced more useful white-space and roadmap recommendations
Both Cypris and Claude suggested alternatives to conventional latex-based particle systems. Copilot's recommendations were less insightful.
The quality of the alternatives, however, was different. Claude's output was more general and matter-of-fact. It identified possible approaches but did not translate them into strong white-space guidance.
Cypris proposed more technically credible alternatives and connected them more directly to a differentiated development strategy. Its roadmap recommendations were clearer about which directions merited further investigation and how the research could be sequenced.
The alternatives included non-latex and ceramic-based particle systems. The evaluation did not establish that every proposed direction was commercially viable, but Devon knew that some ceramic particles had progressed at least as far as commercial trials. Cypris therefore surfaced technically relevant research leads rather than merely generating hypothetical possibilities.
Specific findings that changed the strategic value of the output
Scenario Two: HPMC in Osmotic Drug Delivery
The baseline outputs were more similar
The osmotic drug-delivery scenario produced less separation between the three systems.
All three generated credible summaries of osmotic pump technology and identified, to varying degrees, the grades and functions of HPMC in the existing landscape. Devon found relatively little to distinguish the tools on the initial market, manufacturer and prior-art questions.
The systems also converged on a similar roadmap recommendation: use a Design of Experiments process to optimize HPMC for the different roles it plays in the formulation.
While technically valid, Devon considered that recommendation underwhelming. It represented a standard development methodology rather than a differentiated technical insight.
Cypris generated the most promising next research direction
The difference appeared when Cypris suggested a possible connection between osmotic delivery and the challenge of formulating poorly soluble drugs.
Many active pharmaceutical ingredients have limited aqueous solubility, creating substantial formulation and absorption challenges. Cypris' analysis pointed toward a possible connection with hydroxypropyl methylcellulose acetate succinate, or HPMCAS, a material used in approaches for poorly soluble drugs.
HPMCAS is distinct from the HPMC traditionally used in osmotic systems, and Cypris did not present the connection as a validated solution. Instead, it surfaced a cross-domain clue that an experienced researcher could recognize and investigate further.
Devon viewed this as a meaningful example of how technical research often progresses. The first search does not always deliver the final answer. A strong research system should also reveal the next productive question.
Cypris did that more effectively. It connected information from an adjacent technical area to the osmotic formulation problem, creating the basis for a more differentiated next prompt and potential research direction.
The Core Finding: Technical Intelligence Begins Where the Summary Ends
The comparison showed that general-purpose AI tools can produce useful technical summaries. Both Claude Opus 5 and Microsoft Copilot identified relevant companies, scientific concepts and prior art across the two scenarios.
Cypris separated itself in the work that followed:
- Recognizing a technical failure mode that could derail a development program
- Identifying ownership changes and outdated IP that altered the competitive landscape
- Finding adjacent applications such as thermal printing
- Producing more specific white-space guidance
- Connecting evidence to a clearer R&D roadmap
- Generating cross-domain clues that informed the next research question
This distinction reflects the role of the intelligence layer surrounding the foundation model. A general-purpose model is optimized to explain the available information coherently. A technical intelligence system must also organize patents, scientific literature, companies, materials and market signals into a structure that supports decisions.
Final assessment
Across the four prompts, Cypris produced the strongest overall performance.
The advantage was clearest in the hollow particle scenario, where Cypris demonstrated superior technical analysis, stronger IP intelligence, more credible white-space identification and more actionable roadmap recommendations. Claude Opus 5 was capable of producing credible summaries and some alternative ideas, but remained more general and missed important IP changes and white-space implications. Microsoft Copilot met the baseline requirement for landscape summarization but provided the least differentiated strategic guidance.
The osmotic delivery scenario was more competitive, but Cypris still produced the most promising next research direction by connecting the problem to an adjacent material and formulation challenge.
The conclusion was not simply that Cypris found more information. It more consistently identified the information that mattered.
For an experienced technical leader, that is the difference between receiving a summary of the landscape and receiving the raw material required to build a technology strategy.
Former Dow Research Fellow Compares Cypris, Copilot & Claude for Chemical Intelligence
All Blogs
Quantum computing has become the most dynamic segment of a rapidly expanding quantum patent landscape, and its structure is being set now, well before the technology is commercially mature. According to a joint study by the OECD and the European Patent Office, international patent families in quantum technologies grew sevenfold between 2005 and 2024 and have expanded at a compound annual growth rate of around 20 percent since 2014, far outpacing the 2 percent annual growth observed across all technologies, with quantum computing the field's most dynamic segment.¹ A peer-reviewed patent-landscape analysis puts additional numbers on the trend: about 29,700 quantum patents were granted worldwide between 2001 and 2025 at a compound annual growth rate near 14.5 percent, with more than 40 percent of those grants occurring in the last four years and the USPTO and EPO together now granting roughly 2,500 quantum patents per year.² An independent count across the Cypris corpus of more than 500 million patents and scientific papers shows the same acceleration concentrated in computing: quantum-computing patent families grew from roughly 250 in 2014 to more than 6,300 in 2024, with 2025 counts partial because of the publication lag. For R&D and IP teams, the strategic question is which qubit modality and layer to back, and where defensible positions remain, and both are patent-landscape questions.
The landscape divides across competing qubit modalities, each a distinct region of patenting with different owners and maturity. Across the Cypris corpus, superconducting qubits, including transmon and fluxonium designs, are the most heavily patented hardware route, well ahead of photonic qubits, which come second; a large and strategically critical error-correction and fault-tolerance cluster follows, then topological, semiconductor spin, and trapped-ion approaches, with quantum annealing a further distinct method. The assignee record maps onto that structure: the most active filers include IBM and Google, followed by Microsoft, D-Wave, Baidu, Fujitsu, Intel, and Northrop Grumman, alongside specialized firms such as IonQ, Rigetti, and Quantinuum, whose modality choices track the split between superconducting and trapped-ion routes. Error correction matters because current devices are noisy and a single logical qubit may require on the order of dozens or more physical qubits, making error-correction IP a foundational and heavily contested area. The academic and government roots of the field are visible in the patent record, as much foundational work was supported by national research programs.
Two features shape the strategic picture. First, quantum hardware patents behave more like semiconductor-device patents than software patents: they protect specific physical configurations, materials, and fabrication processes, and are consequently harder to design around, a distinction sharpened by the narrowing of software-patent eligibility since the US Supreme Court's Alice decision in 2014.³,⁴ A patent on a key fabrication step for superconducting qubits, for example, can affect every maker of that hardware, not only direct competitors. Second, the field is entering a more focused phase: the OECD-EPO analysis found that after a decade of exceptional growth the sector is entering a new phase in which rapid expansion gives way to more focused development and maturing technologies,¹ and bibliometric analysis of the field similarly reads it as maturing.⁵ National strategies reinforce this, with the OECD tracking close to 250 quantum policies across 40 countries and the European Union, and the US extending its National Quantum Initiative through the CHIPS and Science Act of 2022.⁶ Because applications publish about eighteen months after filing, the most recent activity is under-represented.
Where the quantum white space is
Error correction. Reducing the physical-qubit overhead per logical qubit is the central unsolved problem and a foundational, heavily contested IP area with room for high-value positions.
Less-crowded modalities. Photonic, semiconductor spin, and topological approaches are earlier and less densely patented than superconducting qubits, offering more white space.
Control and cryogenic systems. Scalable control electronics, cryogenic signal distribution, and calibration are enabling layers where activity is comparatively sparse.
Application and algorithm layers. Domain-specific quantum algorithms and applications, distinct from hardware, are a differentiated area away from the crowded hardware ground.
Fabrication processes. Because hardware patents are hard to design around, specific fabrication and materials processes are high-value, defensible targets.
How AI-powered landscape and white space analysis helps
Resolving multiple modalities and layers across a fast-moving, government-seeded field requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by modality and layer across varied terminology, attribution that normalizes corporate, academic, and government filers to canonical entities, and continuous monitoring that tracks a maturing landscape. Because quantum advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier and the white space are moving.
Where Cypris fits
Cypris runs patent landscape and white space analysis for fast-moving deep-tech fields such as quantum computing across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by qubit modality, superconducting, trapped-ion, photonic, semiconductor spin, and topological, and by layer, hardware, control, error correction, and algorithms, and normalizes filers to canonical entities, so a team can resolve which modalities and layers are crowded and which remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying physics research, which is where quantum advances appear first, and captures the strong academic and government contribution. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined modality over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
How fast is quantum patenting growing? Quantum patenting has grown rapidly. According to the OECD and EPO, international patent families in quantum technologies grew sevenfold between 2005 and 2024 and have expanded at a compound annual growth rate of around 20 percent since 2014, far outpacing the 2 percent growth across all technologies, with quantum computing the most dynamic segment. A peer-reviewed analysis counts about 29,700 quantum patents granted from 2001 to 2025 at a compound annual growth rate near 14.5 percent.
What are the main qubit modalities in the patent landscape? The main qubit modalities are superconducting qubits, trapped-ion qubits, photonic qubits, semiconductor spin qubits, and topological qubits, with quantum annealing a further distinct approach. Superconducting qubits are the most heavily patented hardware route. Each modality is a distinct region of the landscape with different owners and maturity.
Why is quantum error correction a key IP area? Quantum error correction is a key IP area because current quantum devices are noisy and a single logical qubit may require on the order of dozens or more physical qubits. Overcoming this overhead is the central unsolved problem, so error-correction methods are foundational and heavily contested. They cut across all hardware modalities.
How are quantum hardware patents different from software patents? Quantum hardware patents protect specific physical configurations, materials, and fabrication processes, so they behave more like semiconductor-device patents than software patents. They are consequently harder to design around, a distinction sharpened by the narrowing of software-patent eligibility since the US Supreme Court's Alice decision in 2014. A key fabrication patent can affect every maker of that hardware.
Is the quantum landscape maturing? The quantum landscape shows signs of maturing. The OECD-EPO analysis found that after a decade of exceptional growth the sector is entering a new phase in which rapid expansion gives way to more focused development, even as patenting continues. This makes early, defensible positions more valuable.
Where is the white space in quantum computing? The white space in quantum computing includes error correction, the less-crowded modalities such as photonic, semiconductor spin, and topological qubits, control and cryogenic systems, application and algorithm layers, and specific fabrication processes. Superconducting-qubit hardware is comparatively crowded. The higher-value opportunities are in error correction and less-patented modalities.
Why does quantum analysis need scientific literature? Quantum analysis needs scientific literature because quantum advances appear in physics research before they are patented, and much foundational work is academic and government-funded, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams use quantum computing patent landscape analysis? Quantum computing patent landscape analysis is used by R&D, IP, and strategy teams at technology companies, quantum startups, national laboratories, and universities, as well as investors assessing quantum assets. It informs which modality and layer to back, where to file, and where freedom-to-operate risk sits. Cypris serves hundreds of enterprise customers across research-intensive and regulated industries.
Endnotes
- OECD & European Patent Office (2025). Mapping the global quantum ecosystem: a comprehensive analysis based on innovation, firm, investment, skills, trade and policy data. EPO, Munich / OECD Publishing, Paris. https://www.oecd.org/en/publications/mapping-the-global-quantum-ecosystem_010c37da-en.html
- Minssen, T., Aboy, M., & Crespo, C. (2025). Mapping the patent landscape of quantum technologies: evolving patenting trends and policy implications (2025 update). Perspectives in Law, Business and Innovation. https://doi.org/10.1007/978-981-95-8371-3_4
- Kop, M., Minssen, T., & Aboy, M. (2022). Intellectual property in quantum computing and market power: a theoretical discussion and empirical analysis. Journal of Intellectual Property Law & Practice, 17(8). https://doi.org/10.1093/jiplp/jpac060
- Alice Corp. Pty. Ltd. v. CLS Bank International, 573 U.S. 208 (2014). US Supreme Court. https://www.law.cornell.edu/supct/cert/13-298
- Haunschild, R., Scheidsteger, T., Bornmann, L., & Ettl, C. (2021). Bibliometric analysis in the field of quantum technology. Quantum Reports, 3(3). https://doi.org/10.3390/quantum3030036
- OECD (2025). Quantum technologies: national strategies and policy overview. OECD, Paris. https://www.oecd.org/en/topics/sub-issues/quantum-technologies.html
Claude is a formidable reasoner, but unaided it answers patent and scientific questions from training data — and training data is not the patent record. The constraint is not intelligence; it is access. Without a live connection, Claude can overlook recent filings, misstate priority dates, or fabricate a patent number with complete confidence. The Model Context Protocol (MCP) closes that gap. It connects Claude to an authoritative source, so the model retrieves real records and reasons over them rather than reconstructing them from memory.
MCP is the open standard Anthropic introduced in late 2024, now supported across every major AI platform. Within the Claude ecosystem, Claude Desktop, Claude Code, and Claude Science each act as an MCP host that can call external connectors. This article sets out how those connectors work, how to connect patent and scientific data to Claude, and why the connector you choose determines the quality of the answer far more than the act of connecting.
How MCP works in Claude
An MCP host — Claude Desktop, Claude Code, or Claude Science — runs a client that discovers available connectors and translates a request into structured tool calls. The connector authenticates to the data source, formats the query, and returns structured records; Claude then reasons over them in the conversation. Connectors are configured in Claude's settings, not built from scratch, and MCP's security model rests on OAuth-scoped tokens and read-only access — the controls that make connecting external data defensible in an enterprise setting.
The effect is consequential. A plain-language question in Claude becomes a genuine query against a patent or scientific source, and the returned records are available for Claude to analyze, summarize, and cite with provenance.
What you can connect
A growing set of open-source MCP connectors expose public patent and scientific sources to Claude. Connectors exist for USPTO data through Patent Public Search and the Open Data Portal, for the EPO through the OPS API, and for Google Patents through third-party APIs, alongside academic connectors for arXiv and PubMed. Independent projects such as Patent Connector link Claude directly to official patent-office data across multiple jurisdictions.
These connectors solve access. They let Claude retrieve records from a named authority in natural language, eliminating the copy-paste workflow and the transcription errors a model makes when it reads patent data off a web page.
Access is the easy part
Connecting Claude to a dataset is now trivial. Reasoning over it is not. A point connector hands Claude an undifferentiated stream of records from a single source and delegates all interpretation to the model — and the evidence on context engineering is unambiguous: flooding a model with a large, unscoped set of records degrades accuracy rather than improving it.
Most open-source connectors also cover a single source. A complete R&D question spans the patent record and the scientific literature at once, so answering it through point connectors means running several and reconciling their output by hand. For an isolated lookup that is acceptable; for prior art, freedom-to-operate, or landscape work, it reinstates the very fragmentation MCP was meant to eliminate.
Point connector versus domain-oriented agent
The decisive distinction is between a connector that exposes a dataset and an agent built around a domain. A domain-oriented agent is shaped around a field's data, ontology, and workflows, so retrieval is scoped before it ever reaches Claude's context. Instead of returning everything a keyword matches, it surfaces the high-signal patents and papers that bear on the question. Access alone does not make Claude reason well about patents; the domain layer does.
This matters most in Claude Science, Claude's environment for analytical research. Claude Science reasons powerfully over technical material but carries none of the competitive and landscape context held in the patent and scientific record. A domain-oriented agent connected through MCP supplies precisely that signal, so an agent reasoning about a research problem can also judge whether it aligns with where the field is heading.
Connecting patent data to Claude in practice
Cypris exposes its intelligence layer to Claude through an MCP server, so the competitive and landscape context it maintains connects directly into Claude Desktop, Claude Code, or Claude Science. Rather than handing Claude a broad dataset, it applies a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers to scope retrieval to what a question actually requires.
Cypris Q, the platform's agentic layer, runs prior art, white space, freedom-to-operate, and regulatory workflows and returns cited output; Agentic Monitoring keeps a position current as new records publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
Can Claude search patents using MCP?
Claude can search patents using MCP when a patent connector is added through its settings, with Claude Desktop and Claude Code acting as MCP hosts. Claude calls the connector's search and retrieval tools and reasons over the returned records, which lets it work from real filings rather than training data.
How do I connect patent data to Claude?
You connect patent data to Claude by adding an MCP connector in Claude's settings, then letting Claude call that connector's tools during a conversation. The connector authenticates to a patent source and returns structured records, so a plain-language question becomes a real query rather than a recall from memory.
What is Claude Science and how does it use MCP?
Claude Science is Claude's environment for analytical research work, and it supports MCP connectors. Because it is strong at reasoning but does not carry patent and competitive landscape context, connecting a domain-oriented agent through MCP supplies that external signal to its analysis.
What is the difference between Claude Desktop and Claude Code for MCP?
Claude Desktop and Claude Code are both MCP hosts that can call connectors, differing mainly in setting: Claude Desktop is the general assistant environment, while Claude Code is oriented to engineering workflows. Either can connect to a patent or scientific data source through MCP.
Which open-source MCP connectors work with Claude?
Open-source MCP connectors for Claude include ones for USPTO Patent Public Search and the Open Data Portal, the EPO OPS API, Google Patents through third-party APIs, and academic sources such as arXiv and PubMed. Most cover a single source, so spanning patents and literature usually means running several.
Is connecting Claude to a dataset enough for patent research?
Connecting Claude to a dataset solves access but not reasoning, because a raw connector floods the model with records and an overwhelmed model reasons less accurately. Pairing retrieval with a domain ontology, so only high-signal records reach Claude, is what produces reliable analysis.
What is the difference between a point connector and a domain-oriented agent?
A point connector exposes one dataset and leaves interpretation to Claude, while a domain-oriented agent is built around a field's data, ontology, and workflows and scopes retrieval before it reaches the model. The connector improves retrieval; the agent improves the answer.
Can Cypris and Claude be used together?
Cypris and Claude can be used together, because Cypris exposes its intelligence layer through an MCP server and Claude supports MCP connectors, including in Claude Science. The landscape and competitive context Cypris maintains can be connected into Claude so an agent draws on external signal while it reasons.
Are MCP connectors secure for enterprise use with Claude?
MCP's security model relies on OAuth-scoped tokens and read-only access patterns, which is what makes connecting external data to Claude viable for enterprise use. Enterprise deployments should also confirm workspace-level controls and how data is handled with the underlying model provider.
What is the best way to give Claude patent and scientific data?
The best way to give Claude patent and scientific data for R&D work is a domain-oriented agent rather than a raw connector, because stage-gate work spans patents and literature and requires reasoning, not just retrieval. Cypris connects to Claude through an MCP server over a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology.
.jpg)
Regulatory intelligence is the discipline of tracking the approvals, submissions, guidance, and standards that decide whether a technology can reach the market. In regulated industries it stands alongside patent and scientific intelligence as a gate on every R&D program. A technology can be genuinely novel, fully patent-clear, and still be blocked, delayed, or reshaped by a single regulatory decision.
The signals are public but scattered across many bodies and formats: approvals and clearances, submission and trial records, guidance documents and rule changes, standards, labeling, and safety actions. Their value is highest early — before a rule change or a competitor's approval is widely understood. This article sets out how AI-powered regulatory intelligence works for R&D teams in 2026, and how it connects to the patent and scientific record.
What regulatory intelligence covers
Regulatory intelligence spans the full regulatory footprint of a technology area: approvals and clearances, submissions and clinical or field trial records, agency guidance and rule changes, technical standards, labeling requirements, and safety actions such as recalls. The relevant bodies differ by sector — drug and device regulators, environmental and chemical agencies, standards organizations — but the task is constant: know what has changed, what is pending, and what it means for a program.
The payoff is lead time and avoided risk. A competitor's submission reveals its direction and timeline. A guidance change can open or foreclose a development path. Catching either early is the difference between steering a program and being overtaken by a decision after the fact.
Why manual regulatory tracking lags
Manual regulatory tracking means monitoring dozens of agency websites and databases separately, then compiling findings by hand. It is slow, and it is partial. Keyword-based tracking misses documents that describe the same technology or requirement in different terms, and single-source monitoring severs the connection between a regulatory signal and the patent or scientific activity around the same technology.
It is also episodic. A periodic regulatory report is stale the moment a new decision publishes, and the window between refreshes is precisely where a missed signal becomes a missed deadline. Rising regulatory activity across sectors only widens that gap.
How AI-powered regulatory intelligence works
AI-powered regulatory intelligence replaces periodic keyword monitoring with continuous, meaning-based retrieval. Semantic search surfaces relevant approvals, submissions, and guidance by concept, so a signal registers even when it uses unfamiliar terminology. An R&D ontology organizes those signals by technology domain, tying each regulatory event to the specific technology and the organizations pursuing it.
Continuous monitoring runs the analysis without waiting for a scheduled review. It interprets each new regulatory signal against a defined domain, separates the material from the routine, and delivers contextualized alerts rather than raw document links. Because agents span sources, regulatory events can be correlated with patents, scientific literature, and corporate activity into a single picture of where a technology and its competitors are moving.
Connecting regulatory signals to patents and science
Regulatory intelligence is most valuable when it is not siloed. A regulatory decision is one input to a stage-gate, alongside prior art, freedom-to-operate, and the competitive landscape. Connecting regulatory signals to the patent and scientific record lets a team see that a competitor's approval aligns with a filing cluster and a research push — a far stronger signal than any one source read alone.
This is the shift AI enables: from monitoring agencies one at a time to interpreting regulatory change in the context of the full technology picture, and from a static report to intelligence that updates the moment decisions publish.
Regulatory intelligence in practice
Cypris is an AI-native R&D intelligence platform whose Agentic Monitoring capability tracks regulatory bodies continuously, alongside patent offices, scientific literature, M&A activity, product launches, grant awards, and corporate news. It interprets these signals through a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers, so a regulatory event is tied to the technology and the organizations it concerns rather than read in isolation.
Cypris Q, the platform's agentic layer, lets teams move from a regulatory signal into prior art, white space, or freedom-to-operate analysis on the same technology, in one environment, with cited output. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is regulatory intelligence for R&D?
Regulatory intelligence for R&D is the practice of tracking the approvals, submissions, guidance, and standards that determine whether a technology can reach the market. It sits alongside patent and scientific intelligence as a gate on a program, because a technology can be patent-clear and still be blocked or delayed by a regulatory decision.
How is regulatory intelligence different from patent monitoring?
Regulatory intelligence tracks regulatory signals such as approvals, submissions, and guidance, while patent monitoring tracks filings. Both gate an R&D program, and the fullest picture comes from correlating them, since a competitor's approval often aligns with its patent and research activity.
What signals does regulatory intelligence track?
Regulatory intelligence tracks approvals and clearances, submissions and trial records, agency guidance and rule changes, technical standards, labeling requirements, and safety actions such as recalls. The relevant bodies vary by sector, but the task is to know what has changed, what is pending, and what it means.
Why does regulatory intelligence matter for R&D?
Regulatory intelligence matters for R&D because a regulatory decision can open or close a development path regardless of a technology's novelty or patent position. Catching a guidance change or a competitor's submission early is the difference between adjusting a program and being caught by a decision after the fact.
How does AI improve regulatory intelligence?
AI improves regulatory intelligence by replacing periodic keyword monitoring with continuous semantic retrieval, so relevant approvals, submissions, and guidance are found by concept even when terminology differs. An R&D ontology then organizes the signals by domain and connects them to the technology and organizations involved.
Can regulatory signals be tracked continuously?
Regulatory signals can be tracked continuously with agentic monitoring that interprets new decisions against a defined technology domain and delivers contextualized alerts as they publish. This replaces periodic manual reports, which are stale as soon as a new decision appears.
How does regulatory intelligence connect to patents and science?
Regulatory intelligence connects to patents and science when the same platform correlates a regulatory event with the filings and research around the same technology. This produces a stronger signal than any single source, and it lets a regulatory decision feed directly into prior art or freedom-to-operate review.
Which sectors rely most on regulatory intelligence?
Regulated industries rely most on regulatory intelligence, including pharmaceuticals, medical devices, chemicals, advanced materials, and energy, where approvals and standards gate commercialization. In these sectors a regulatory signal can reshape an R&D program's timeline and direction.
What public sources support regulatory intelligence?
Public sources that support regulatory intelligence include agency databases and registers such as those published by drug, device, environmental, and standards bodies, along with trial registries and official rule-change publications. Unifying and interpreting these fragmented sources is what an AI-powered platform adds.
What is the best platform for regulatory intelligence in R&D?
The best platform for regulatory intelligence in R&D tracks regulatory signals continuously and connects them to the patent and scientific record. Cypris tracks regulatory bodies through Agentic Monitoring alongside patents, literature, and corporate signals, interpreted through a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers.
ChatGPT is the assistant many R&D and IP teams already use, but on its own it answers patent questions from training data. It can miss recent filings, confuse filing and publication dates, or produce a patent number that does not exist. Connecting ChatGPT to a live source through the Model Context Protocol (MCP) fixes this, so it retrieves real records and reasons over them.
MCP is an open standard introduced by Anthropic in late 2024 and now supported across the major AI platforms, ChatGPT among them. This article explains how ChatGPT's connectors and apps work, how to connect patent and scientific data, and why the choice of connector determines whether the output is reliable.
How connectors and apps work in ChatGPT
ChatGPT connects to external data through MCP-based apps. OpenAI renamed connectors to apps in December 2025, and in 2026 moved the app directory into a broader plugin directory, but the underlying mechanism is unchanged: an app is an MCP integration that lets ChatGPT call approved tools and retrieve information from a service. Custom MCP servers are added through Developer Mode, and on workspace plans administrators control whether custom apps are allowed and how they roll out.
Once connected, ChatGPT can call the app's tools during a chat or in deep research, so a plain-language question becomes a structured query against a patent or scientific source. MCP's security model relies on OAuth-scoped tokens and read-only access patterns, which keeps the connection appropriate for enterprise use.
What you can connect
Several open-source MCP servers expose public patent and scientific sources to ChatGPT. There are connectors for USPTO data through Patent Public Search and the Open Data Portal, for the EPO through the OPS API, and for Google Patents through third-party APIs, alongside academic connectors for arXiv and PubMed. Independent projects such as Patent Connector link ChatGPT directly to official patent-office data across several jurisdictions.
These connectors solve access. They let ChatGPT retrieve records from a specific authority in natural language, which removes the manual copy-paste loop and the errors a model makes when it reads patent data off a web page.
Access is the easy part
Connecting ChatGPT to a dataset is now straightforward. Reasoning over it well is the harder problem. A point connector hands ChatGPT a stream of raw records from one source and leaves interpretation to the model, and research on context engineering shows that flooding a model with a large, undifferentiated set of records degrades accuracy rather than improving it.
Most open-source connectors also cover a single source, so a question that spans the patent record and the scientific literature usually means running several apps and reconciling their output by hand. That is acceptable for a quick lookup but not for prior art, freedom-to-operate, or landscape work.
Point connector versus domain-oriented agent
The meaningful distinction is between an app that exposes a dataset and an agent built around a domain. A domain-oriented agent is shaped around a field's data, ontology, and workflows, so retrieval is scoped before it reaches ChatGPT's context. Rather than returning everything a keyword matches, it retrieves the high-signal patents and papers relevant to the question. Access alone does not make ChatGPT reason well about patents; the domain layer does.
For teams on workspace plans, this also simplifies governance. A single domain-oriented app under administrator control is easier to manage and audit than a stack of point connectors, each with its own source, credentials, and maintenance burden.
Connecting patent data to ChatGPT in practice
Cypris exposes its intelligence layer through an MCP server, so its competitive and landscape context can be connected into ChatGPT as an app. Rather than handing ChatGPT a broad dataset, it uses a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers to scope retrieval to what matters for a question, and returns source-traceable results ChatGPT can cite.
Cypris Q, the platform's agentic layer, runs prior art, white space, freedom-to-operate, and regulatory workflows and returns cited output, and Agentic Monitoring keeps a position current as new records publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
Can ChatGPT search patents using MCP?
ChatGPT can search patents using MCP when a patent app or connector is added, after which it calls the app's tools to retrieve records during a chat or deep research. This lets ChatGPT work from real filings rather than training data, which removes the hallucination and stale-coverage problems of answering from memory.
How do I connect patent data to ChatGPT?
You connect patent data to ChatGPT by adding an MCP-based app, typically a custom MCP server through Developer Mode, subject to any workspace controls. Once connected, ChatGPT can call the app's tools so a plain-language question becomes a structured query against a patent source.
What are ChatGPT apps and connectors?
ChatGPT apps are MCP integrations that let ChatGPT call approved tools and retrieve information from a service; OpenAI renamed connectors to apps in December 2025 and later organized them in a plugin directory. The mechanism is MCP, so the same standard used by other assistants applies.
What is Developer Mode in ChatGPT?
Developer Mode is the setting that lets you add custom MCP servers to ChatGPT beyond the built-in apps. It is how a team connects a specific patent or scientific data source that is not already offered as a packaged app.
Which open-source MCP connectors work with ChatGPT?
Open-source MCP connectors for ChatGPT include ones for USPTO Patent Public Search and the Open Data Portal, the EPO OPS API, Google Patents through third-party APIs, and academic sources such as arXiv and PubMed. Most cover a single source, so spanning patents and literature usually means running several.
Is connecting ChatGPT to a dataset enough for patent research?
Connecting ChatGPT to a dataset solves access but not reasoning, because a raw connector floods the model with records and an overwhelmed model reasons less accurately. Pairing retrieval with a domain ontology, so only high-signal records reach ChatGPT, is what produces reliable analysis.
How do enterprise controls work for ChatGPT apps?
On workspace plans, administrators control whether custom apps are allowed and how they roll out, which lets an organization govern what data ChatGPT can reach. Combined with MCP's OAuth-scoped, read-only access model, this is what makes connecting external data appropriate for enterprise use.
What is the difference between a point connector and a domain-oriented agent?
A point connector exposes one dataset and leaves interpretation to ChatGPT, while a domain-oriented agent is built around a field's data, ontology, and workflows and scopes retrieval before it reaches the model. The connector improves retrieval; the agent improves the answer, and it is also easier to govern as a single app.
Can Cypris and ChatGPT be used together?
Cypris and ChatGPT can be used together, because Cypris exposes its intelligence layer through an MCP server and ChatGPT connects to MCP servers as apps. The landscape and competitive context Cypris maintains can be connected into ChatGPT so it reasons over scoped, source-traceable records.
What is the best way to give ChatGPT patent and scientific data?
The best way to give ChatGPT patent and scientific data for R&D work is a domain-oriented agent rather than a raw connector, because stage-gate work spans patents and literature and requires reasoning, not just retrieval. Cypris connects to ChatGPT through an MCP server over a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology.
Keyword search matches exact terms. Semantic search matches meaning. For patent search, that distinction determines whether a strategically critical filing is found or missed.
Patent search has relied on Boolean keyword queries and classification codes for decades. The method works when the searcher already knows the exact language an invention will use. It fails when a competitor describes the same mechanism with different words, files under a different classification, or uses terminology that did not exist when the query was written. In fast-moving fields, that failure is routine.
In 2026, R&D and IP teams are moving to AI-native semantic patent search because the volume and linguistic variety of global filings have outpaced keyword methods. This article defines semantic search, contrasts it with keyword search, and explains what the shift changes for patent search, patent analytics, prior art, and freedom-to-operate work.
How keyword patent search works and where it breaks
Keyword search retrieves documents that contain the specific terms in a query, usually combined with Boolean operators and classification filters. It is precise when the vocabulary is known and stable, and it remains useful for targeted lookups.
It breaks on vocabulary mismatch. Two teams working on the same problem often use entirely different terminology, and patent drafters frequently choose broad or unusual language deliberately. A keyword query built around expected terms will not retrieve a filing that describes the same invention differently. The result is silent gaps: the searcher sees results and assumes coverage, without knowing what was missed.
Volume magnifies the problem. Global patent filings and scientific publications continue to rise, and the World Intellectual Property Organization reported scientific output above two million articles in 2025. Expanding keyword queries to chase this volume produces either too much noise or too little signal.
How semantic search works
Semantic search represents the meaning of text as mathematical vectors, so that conceptually similar passages sit close together regardless of exact wording. A query for a mechanism retrieves filings that describe that mechanism, even when the words differ. This directly addresses the vocabulary-mismatch problem that keyword search cannot solve.
For patents, the strongest implementations apply semantic search at the claim level and across both patents and scientific literature. Claim-level retrieval matters because the legal risk in a patent lives in its claims, not its abstract. Searching patents and scientific papers together matters because early technical disclosure often appears in the literature before it reaches granted claims.
An R&D ontology strengthens semantic search further. An ontology is a structured map of technical concepts and their relationships. When semantic retrieval is organized through an ontology, as it is on AI-native platforms such as Cypris, the system interprets a query in the context of a technology domain rather than as isolated words, which improves both recall and precision.
What the shift changes for R&D and IP teams
Semantic search changes prior art and FTO work most directly. In prior art search, semantic retrieval surfaces conceptually relevant disclosures that keyword queries overlook, which strengthens both patentability assessments and invalidity arguments. In freedom-to-operate search, it surfaces active claims a product may read on even when those claims use unexpected language, reducing unquantified legal risk.
It also changes patent analytics. Once retrieval understands meaning, analytics can group filings by technical concept rather than by literal text, producing cleaner technology landscapes, competitor maps, and white space analysis. Agentic workflows build on this by chaining retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions automatically.
Semantic search in practice
Cypris is an AI-native R&D intelligence platform built on semantic search across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology lets Cypris interpret technical meaning and retrieve conceptually related patents and literature at the claim level, rather than matching keywords.
Cypris Q, the platform's agentic layer, chains semantic retrieval and reasoning into end-to-end workflows such as landscape analysis, prior art review, and FTO assessment. Agentic Monitoring keeps those positions current by evaluating new filings as they publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is semantic search for patents?
Semantic search for patents retrieves filings by meaning rather than by exact keywords, representing text as vectors so that conceptually similar patents sit close together. This surfaces relevant patents that use different terminology than a query expects, which keyword search cannot do.
What is the difference between semantic search and keyword search?
Semantic search matches the meaning of text, while keyword search matches exact terms combined with Boolean operators. Keyword search misses filings that describe the same invention in different words, whereas semantic search retrieves them because it operates on concepts rather than literal strings.
Why are R&D teams moving to AI-native patent search?
R&D teams are moving to AI-native patent search because the volume and linguistic variety of global filings have outpaced keyword methods, causing silent gaps in coverage. Semantic search retrieves conceptually related filings across patents and scientific literature, reducing the risk that critical disclosures are missed.
Is semantic search better than keyword search for prior art?
Semantic search is generally stronger for prior art because it surfaces conceptually relevant disclosures that keyword queries overlook due to vocabulary mismatch. Keyword search remains useful for targeted lookups when the exact terminology is known, so many workflows combine both.
What is an R&D ontology in patent search?
An R&D ontology is a structured map of technical concepts and their relationships that organizes a search corpus by meaning. In patent search, an ontology lets a system interpret a query in the context of a technology domain rather than as isolated words, improving both recall and precision.
Does semantic search work across patents and scientific papers?
Semantic search works across both patents and scientific papers when the corpus unifies them, which matters because early technical disclosure often appears in the literature before it reaches granted patent claims. Searching both together produces a more complete technical and competitive picture.
How does semantic search improve patent analytics?
Semantic search improves patent analytics by grouping filings by technical concept rather than literal text, which produces cleaner technology landscapes, competitor maps, and white space analysis. Analytics built on meaning are more reliable than analytics built on keyword matches alone.
Can semantic patent search be automated with agents?
Semantic patent search can be automated with agentic workflows that chain retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions. Agents keep the analysis current by re-running semantic retrieval against new filings as they publish.
Does semantic search replace Boolean patent search entirely?
Semantic search does not fully replace Boolean patent search, because targeted keyword queries remain useful when exact terminology is known. The strongest workflows combine semantic retrieval for recall with keyword precision for confirmation.
What data coverage does effective semantic patent search require?
Effective semantic patent search requires broad coverage across patents and scientific literature, so that conceptually related disclosures in any vocabulary can be retrieved. A corpus of more than 500 million patents and scientific papers organized through an R&D ontology supports this breadth.
R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates instead of dissipating. Every program produces reports, experiments, analyses, and decisions, and most of that knowledge is scattered across documents and people. When it cannot be found, it is repeated, and when a person leaves, it is lost.
The cost is concrete. Teams re-run experiments that were already done, revisit questions that were already answered, and lose the reasoning behind past decisions when the people who made them move on. This is the tribal knowledge problem, and it compounds negatively as an organization grows. This article explains how AI-powered knowledge management changes that, and how internal knowledge becomes most valuable when connected to the external research record.
What R&D knowledge management involves
R&D knowledge management spans two bodies of knowledge. The first is internal: research reports, experimental results, technical decisions, and the reasoning behind them. The second is external: the patents, scientific literature, and competitive activity that place internal work in context. The goal is to make both retrievable in a way that reflects how researchers actually think about a problem, rather than by filename or folder.
The defining requirement is retrieval by meaning. A researcher rarely knows the exact document title or keyword; they know the problem. Knowledge management is only useful if a question about a compound, a method, or a decision returns the relevant internal work regardless of how it was originally labeled.
Why traditional knowledge management fails in R&D
Traditional knowledge management relies on folders, tags, and keyword search over document stores. It fails in R&D for the same reasons keyword search fails elsewhere: the same concept is described in different words across teams and years, so a query built on expected terms misses relevant work. Documents are siloed by team and system, and the connection between a past experiment and a current question is invisible.
It also fails at the human boundary. When knowledge lives in individuals rather than a retrievable system, staff turnover erases it. A traditional document repository preserves files but not the ability to find the right one at the right moment, which is the part that actually matters.
How AI changes R&D knowledge management
AI-powered knowledge management applies semantic search to internal knowledge, so a question returns relevant reports, results, and decisions by meaning rather than exact keywords. An R&D ontology organizes that knowledge by technical concept and connects related work, so a current problem surfaces the past work that bears on it even when the vocabulary differs.
The larger shift is connecting internal knowledge to the external record. When internal research is organized in the same conceptual structure as the external patent and scientific literature, a single question can reach both: what the team already knows, and what the wider field has published or patented. That connection is what turns a static archive into an intelligence layer.
Why connected knowledge compounds
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it. An experiment recorded today becomes findable the next time a related question arises; a past decision retains its reasoning; a current program is checked against both internal history and the external landscape before resources are committed. Instead of decaying as people leave and volume grows, the organization's knowledge becomes more valuable over time.
This is the difference between storing knowledge and compounding it. Storage preserves documents; compounding makes the whole body of work usable on every new question.
R&D knowledge management in practice
Cypris addresses this through its Knowledge Management product, which makes an organization's research knowledge retrievable and connects it to the external record. Internal work is organized through the same proprietary R&D ontology that structures a corpus of more than 500 million patents and scientific papers, so a single semantic query reaches both internal knowledge and the external patent and scientific literature.
Cypris Q, the platform's agentic layer, lets teams interrogate that combined knowledge in natural language and returns cited output, so a question about a compound or a program draws on internal history and external context at once. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is R&D knowledge management?
R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates rather than being lost to silos and turnover. It covers internal reports, experiments, and decisions, and connects them to the external patent and scientific record.
Why does R&D lose institutional knowledge?
R&D loses institutional knowledge because much of it lives in individuals and scattered documents rather than a retrievable system, so it disappears when people leave or when work cannot be found. This tribal knowledge problem leads teams to repeat experiments and lose the reasoning behind past decisions.
Why does traditional knowledge management fail in R&D?
Traditional knowledge management fails in R&D because folder-and-keyword systems miss work described in different terms across teams and years, and they silo documents by system. They preserve files but not the ability to find the right one at the right moment, which is the part that matters.
How does AI improve R&D knowledge management?
AI improves R&D knowledge management by applying semantic search, so a question returns relevant internal work by meaning rather than exact keywords. An R&D ontology organizes knowledge by technical concept and connects related work, and links internal knowledge to the external patent and scientific record.
What is tribal knowledge and why does it matter?
Tribal knowledge is the undocumented understanding held by individuals in an organization, such as why a decision was made or how a method actually works. It matters because it is lost when people leave, and capturing it in a retrievable system is a central goal of R&D knowledge management.
How does knowledge management connect internal work to external research?
Knowledge management connects internal work to external research by organizing both in the same conceptual structure, so a single question reaches internal reports and the external patent and scientific literature together. This places a team's own work in the context of what the wider field has published or patented.
What does it mean for knowledge to compound?
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it, so its value grows over time. Instead of decaying as staff turn over and volume rises, the organization's body of work becomes more usable on every new question.
Is R&D knowledge management just a document repository?
R&D knowledge management is more than a document repository, because storage alone preserves files without making the right one findable at the right moment. The value is in retrieval by meaning and in connecting internal knowledge to the external record, not in archiving.
Which teams benefit most from R&D knowledge management?
Research-intensive organizations benefit most from R&D knowledge management, particularly in pharmaceuticals, chemicals, advanced materials, and energy, where programs are long, knowledge is technical, and turnover erases hard-won understanding. These teams gain the most from preserving and connecting institutional knowledge.
What is the best platform for R&D knowledge management?
The best platform for R&D knowledge management makes internal knowledge retrievable by meaning and connects it to the external research record. Cypris does this through its Knowledge Management product, organizing internal work through the same R&D ontology that structures a corpus of more than 500 million patents and scientific papers.
mRNA therapeutics have moved from pandemic response to a broad modality, and their patent landscape is distinctive because the mRNA molecule is patented separately from the lipid nanoparticle that delivers it. This article addresses the construct itself. A therapeutic mRNA is engineered in several parts, and each is a distinct region of patenting: the modified nucleosides, such as pseudouridine variants, that reduce the innate immune response, an insight foundational to making mRNA usable in humans;¹ the five-prime cap that enables translation;² the untranslated regions that tune expression;³ the poly-A tail that stabilizes the molecule and, with the cap, defines the ends that are engineered for therapeutic performance;⁴ the sequence and codon optimization that improves output; and, increasingly, the self-amplifying and trans-amplifying designs that let a smaller dose replicate inside the cell. Rational-design analyses describe the construct as exactly this layered assembly, from cap through untranslated regions and open reading frame to poly-A tail, and the choice of nucleoside modification continues to shape immunogenicity.⁵,⁶ Because these elements can be claimed independently and are often held by different owners, and because delivery adds its own separate estate, freedom-to-operate for an mRNA product is a multi-layer, multi-owner analysis rather than a single clearance.
The field's IP has been defined by landmark disputes, which have raised the stakes across every layer. Foundational modified-nucleoside discoveries originated in academic work and are licensed through a chain of sublicenses, and the leading commercial developers have litigated over who owns and who may use the core construct technologies. Several of these cases have moved through courts in the United States and through the European Patent Office: one developer's settlement arrangements to resolve pending mRNA vaccine litigation with two others were entered on August 7, 2025,⁷ while a series of European construct patents were revoked or narrowed in opposition proceedings, with a further opposed patent maintained in amended form.⁸ The practical result is that a developer can hold a strong position on its own sequence and still face freedom-to-operate exposure on the nucleoside chemistry, the untranslated regions, or the tail, plus the separate delivery layer. This shows in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the mRNA vaccine and therapeutics set holds on the order of 16,694 families and grew from about 582 in 2020 to roughly 2,062 in 2024, with the most active assignees including ModernaTx, Translate Bio, CureVac, the University of Pennsylvania, MIT, and BioNTech, and the United States far ahead of China and Germany on geography; 2025 and 2026 counts are partial because of the publication lag.
The strategic picture turns on where defensible, hard-to-design-around IP sits. The foundational modified-nucleoside and core-structure estates are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in self-amplifying and trans-amplifying mRNA, in novel nucleoside modifications and sequence-engineering methods, in untranslated-region and structural designs that improve durability and expression, in enzymatic capping and manufacturing methods, and in mRNA applications beyond vaccines.⁷ Self-amplifying mRNA has now reached the market: the first self-amplifying mRNA vaccine, which encodes a replicase alongside the antigen so the molecule copies itself inside the cell, was approved in Japan in 2023 and by the European Commission in February 2025, though not, as of this writing, in the United States.⁹ Circular RNA and other next-generation constructs are a further frontier. Reading the landscape by construct layer and by owner, and tracking both the patents and the underlying RNA-biology research, is what separates a workable position from a blocked one.
What creates FTO risk in mRNA constructs
Modified-nucleoside claims. These cover the chemistries, such as pseudouridine variants, that reduce immune activation, a foundational and heavily licensed layer.¹,⁶
Cap and untranslated-region claims. These cover the five-prime cap and the untranslated regions that enable and tune translation, a distinct expression-control layer.²,³
Poly-A tail and stability claims. These cover the tail and other end-engineering technologies, a separately owned and actively litigated layer.⁴
Sequence and codon-optimization claims. These cover methods to improve protein output from a given sequence, which can carry their own IP.
Self-amplifying and next-generation-construct claims. These cover self-amplifying, trans-amplifying, and circular-RNA designs, an emerging and comparatively open layer.⁹
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant nucleoside, cap, untranslated-region, tail, and self-amplifying claims regardless of terminology, attribution that resolves academic and commercial owners and the sublicense chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because RNA-biology advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as mRNA therapeutics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by construct layer, modified nucleoside, cap, untranslated region, poly-A tail, and self-amplifying design, and normalizes academic and commercial owners and their sublicense chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list, and can separate the construct estate from the delivery estate. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new modifications and constructs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is mRNA construct IP separate from delivery IP? mRNA construct IP is separate from delivery IP because the mRNA molecule and the lipid nanoparticle that carries it are distinct inventions with distinct owners. The construct covers the nucleosides, cap, untranslated regions, tail, and sequence; the delivery covers the lipid formulation. Freedom-to-operate must clear both estates separately.
Why were modified nucleosides so important? Modified nucleosides were important because replacing a natural nucleoside with a modified form, such as a pseudouridine variant, sharply reduced the innate immune response that had previously made mRNA unsuitable as a drug. This breakthrough helped enable therapeutic mRNA. The foundational nucleoside estates are therefore central to the landscape.
What claim types create FTO risk in mRNA constructs? Five claim types create FTO risk: modified-nucleoside claims, cap and untranslated-region claims, poly-A tail and stability claims, sequence and codon-optimization claims, and self-amplifying and next-generation-construct claims. Each covers a distinct layer and can be held by a different owner. The nucleoside and stability layers have been especially contested.
Why has mRNA IP been so heavily litigated? mRNA IP has been heavily litigated because the modality became commercially enormous very quickly, foundational construct technologies are held by a small number of parties, and their scope overlaps. Disputes have run through courts and the European Patent Office, with some resolved by settlement, including arrangements entered in August 2025, and others contested in opposition proceedings. The outcomes shape licensing across the field.
Has a self-amplifying mRNA product been approved? Yes. The first self-amplifying mRNA vaccine, which encodes a replicase so the mRNA copies itself inside cells, was approved in Japan in 2023 and by the European Commission in February 2025. It had not been approved in the United States as of this writing. Self-amplifying designs aim to achieve a given effect at a lower dose.
Where is the white space in mRNA therapeutics? The white space includes self-amplifying and trans-amplifying mRNA, novel nucleoside modifications and sequence engineering, untranslated-region and structural designs, enzymatic capping and manufacturing, circular RNA, and applications beyond vaccines. The foundational construct layers are crowded and licensed. The durable, defensible value is in next-generation constructs and new applications.
What software helps analyze the mRNA therapeutics patent landscape? Software for the mRNA landscape should resolve academic and commercial owners and sublicense chains to canonical entities, separate the construct and delivery estates, cluster the nucleoside, cap, untranslated-region, tail, and self-amplifying layers, search patents and scientific literature semantically, and monitor disputes and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams need mRNA patent landscape and FTO analysis? mRNA patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at mRNA and vaccine companies, as well as investors assessing mRNA assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
Endnotes
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2). https://doi.org/10.1016/j.immuni.2005.06.008
- Kore, A. R., Senthilvelan, A., & Shanmugasundaram, M. (2022). Recent advances in modified cap analogs for mRNA-based vaccines. The Chemical Record, 22(9). https://doi.org/10.1002/tcr.202200005
- Zhang, H., et al. (2024). Optimization of the 5′ untranslated region of mRNA vaccines. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-70792-x
- Jemielity, J., et al. (2023). Chemical modifications of mRNA ends for therapeutic applications. Accounts of Chemical Research, 56(20). https://doi.org/10.1021/acs.accounts.3c00442
- To, K. K. W., & Cho, W. C. S. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 16(11). https://doi.org/10.1080/17460441.2021.1935859
- Liu, Y. (2026). The impact of nucleotide modifications on the immune responses of mRNA vaccines. https://doi.org/10.54097/bmddk068
- CureVac N.V. (2025). CureVac announces resolution of patent litigation with Pfizer/BioNTech (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
- CureVac N.V. (2025). CureVac receives positive validity decision from the European Patent Office in litigation against BioNTech SE (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925028798/tm2510706d1_ex99-1.htm
- European Medicines Agency (2024). Kostaive (zapomeran): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/kostaive-epar-public-assessment-report_en.pdf
Antibody-drug conjugates are among the most active areas of oncology drug development, and their patent landscape is distinctive because an ADC is a modular product whose components are patented separately. An ADC joins a monoclonal antibody to a cytotoxic payload through a chemical linker, using a defined conjugation chemistry and a specified drug-to-antibody ratio. Each of these elements, the antibody, the linker, the payload, the conjugation site and chemistry, and the ratio, can be claimed independently, so freedom-to-operate risk is layered across several distinct patent families held by different owners. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims, and peer-reviewed analysis of ADC intellectual property has long stressed that the assessment must cover every layer, not the molecule as a whole.¹
The landscape has grown intensely. A peer-reviewed update to the ADC patent literature notes that, a decade after the first ADC patent-landscape review, the basic principles still apply but the field has expanded and matured substantially, with next-generation payloads, linkers, and site-specific conjugation driving new filings.² That expansion is visible in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, ADC-specific patent families more than doubled from about 2,645 in 2018 to about 5,949 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag. The growth has been propelled by potent topoisomerase-1 payloads such as the deruxtecan and govitecan classes, new linker and site-specific conjugation technologies, and the expansion of ADCs from hematologic cancers into solid tumors. Peer-reviewed patent reviews map the issued patents onto specific linker and payload technologies,³ and document filing activity concentrated among a small set of leading developers, with more than a dozen approved ADCs and a large clinical pipeline behind the trend.⁴ Within the Cypris corpus, conjugation and site-specific chemistry and the linker layer are the most heavily worked parts of the ADC set, consistent with where litigation and FTO risk concentrate.
Litigation has made the stakes concrete, and it has centered on the linker layer. In the multi-year dispute between Seagen and Daiichi Sankyo over the linker technology used in a blockbuster HER2-targeted ADC, a jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and non-enablement and vacating the damages award.⁵ The court reasoned that the priority disclosure did not convey possession of the specific claimed subgenus of linkers and that a broad functional claim was not enabled.⁵ For developers, the practical lesson is twofold: the linker and conjugation layer is heavily contested and a frequent source of FTO risk, and the proprietary payload estates built around leading platforms, such as the DXd payload, create freedom-to-operate exposure for follow-on and biosimilar ADCs in markets where those estates are in force. That exposure is concentrated: across the Cypris corpus, the most active assignees in the ADC-specific set include Genentech, Seagen, Daiichi Sankyo, Regeneron, Immunomedics, and ImmunoGen, several of which anchor the payload and linker estates most likely to surface in an FTO search. Because applications publish about eighteen months after filing, the newest linker, payload, and conjugation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.
What creates FTO risk in ADCs
Antibody claims. These cover the targeting antibody and its engineering, a distinct layer that can implicate separate antibody IP.
Linker claims. These cover cleavable and non-cleavable linkers and their chemistry, the layer most heavily litigated, as the Seagen v. Daiichi Sankyo dispute demonstrates.⁵
Payload claims. These cover the cytotoxic agent, including proprietary payload estates built around specific classes, which create FTO exposure for follow-on products.
Conjugation and site-specific claims. These cover how payload and antibody are joined and where, an area of intense recent innovation and patenting.³
Drug-to-antibody ratio and formulation claims. These cover the ratio and the finished formulation, adding further independently claimable layers.
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, actively litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant antibody, linker, payload, and conjugation claims regardless of terminology, attribution that resolves the many owners to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and litigation developments. Because ADC advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the landscape is extending.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as antibody-drug conjugates across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, antibody, linker, payload, and conjugation, and normalizes owners to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation linkers and payloads emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is freedom-to-operate hard for antibody-drug conjugates? Freedom-to-operate is hard for antibody-drug conjugates because an ADC is a modular product whose antibody, linker, payload, conjugation chemistry, and drug-to-antibody ratio are each independently patentable and often held by different owners. Clearing one layer does not clear the others. FTO must therefore be assessed layer by layer across multiple patent families.
What are the main claim types in the ADC landscape? The main claim types are antibody claims, linker claims, payload claims, conjugation and site-specific claims, and drug-to-antibody-ratio and formulation claims. Each covers a distinct layer of the ADC and can independently create infringement risk. The linker and conjugation layers are especially heavily patented and litigated.
What was the Seagen v. Daiichi Sankyo dispute about? The Seagen v. Daiichi Sankyo dispute concerned linker technology used in a blockbuster HER2-targeted ADC. A jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and enablement and vacating the award. It illustrates how the linker layer drives ADC freedom-to-operate risk and how even a trial win can be undone on validity grounds.
How fast is ADC patenting growing? ADC patenting has grown rapidly, with ADC-specific patent families more than doubling between 2018 and 2024 in the Cypris corpus. Growth has been driven by potent topoisomerase-1 payloads, new linker and site-specific conjugation technologies, and expansion from hematologic cancers into solid tumors. Because applications publish about eighteen months after filing, recent activity is under-represented.
What is a payload estate and why does it matter for FTO? A payload estate is the set of patents an organization holds around a specific cytotoxic payload class and its use in ADCs. It matters for FTO because a strong payload estate, such as the one around the DXd payload, can create infringement exposure for follow-on and biosimilar ADCs in markets where it is in force. Developers must assess payload IP as a distinct layer.
Why does ADC analysis need scientific literature? ADC analysis needs scientific literature because linker, payload, and conjugation advances appear in research before they are patented, so the literature gives the earliest signal of where the landscape is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams need ADC patent landscape and FTO analysis? ADC patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at pharmaceutical and biotech companies developing ADCs, payloads, linkers, and conjugation platforms, as well as investors assessing ADC assets. The modular, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
How current does an ADC landscape need to be? An ADC landscape needs to be continuously current, because litigation is active, next-generation linker and payload filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.
Battery circularity, the recycling, reuse, and repurposing of batteries, has become the fastest-growing area of battery patenting, and its landscape is a map of the coming competition over critical minerals. According to a joint study by the European Patent Office and the International Energy Agency, international patent families related to battery circularity grew at an average of 42 percent per year from 2017 to 2023, compared with 16 percent for rechargeable battery manufacturing overall and 2 percent across all technical fields.¹ Over the decade the number of these families rose roughly sevenfold.¹ The driver is structural: more than one in four cars sold globally in 2025 was electric, and around 1.2 million electric-vehicle batteries could reach end of life in 2030, rising to 14 million by 2040, so managing and reclaiming that volume is both an environmental necessity and a supply-chain strategy.¹
The landscape is geographically concentrated and shifting quickly. Asian applicants accounted for 63 percent of battery-circularity patent families in 2023, and China's share rose from 5 percent in 2013 to 29 percent in 2023, with Brunp, the recycling subsidiary of a major battery maker, overtaking established Japanese and Korean firms to become the most active filer.¹ European companies and research institutes account for roughly 20 percent of families, with particular strength in the collection and pre-processing of used batteries and in chemical transformation to recover raw materials, reflecting Europe's current role more as a battery user than a producer.¹ An independent count across the Cypris corpus of more than 500 million patents and scientific papers reproduces the same picture: China holds roughly two-thirds of the recycling-specific family set, well ahead of the United States, Germany, South Korea, and Japan, and Brunp is the single most active assignee, ahead of chemical and battery-materials firms such as BASF and Sumitomo Metal Mining. The strategic significance is large: energy storage now represents about 40 percent of all energy-related patenting and is heading toward half, and recycled materials could meet more than a fifth of demand for lithium, nickel, and cobalt by 2040.¹
The technology landscape divides into distinct stages, each a region of patenting. A peer-reviewed patent-network analysis of lithium-ion battery recycling covering 1990 to 2024 finds activity rising steeply since around 2020, with China leading and international collaboration remaining limited,² and bibliometric analysis of the field documents the same long-run acceleration in recycling research and patenting.³ Across the Cypris corpus, hydrometallurgy is the most patented chemical-recovery route, well ahead of pyrometallurgy, while direct recycling and cathode regeneration remain comparatively nascent; a large, separate cluster covers collection, pre-processing, and separation, the earlier stage where Europe is comparatively strong. Metal recovery and cathode regeneration are where much of the chemical innovation and value concentrate, with key work focused on improving leaching efficiency, developing purification methods, and relithiation strategies that restore spent cathode materials. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is even more active than the figures show.
Where the battery-circularity white space is
Direct cathode regeneration. Restoring spent cathode material directly, rather than breaking it down to metals, is a higher-value route that remains comparatively nascent in the patent record, leaving room for defensible positions.²
Efficient metal recovery. Improving leaching efficiency and purification for lithium, nickel, and cobalt is where much chemical innovation concentrates and where recovery economics are decided.²
Collection and pre-processing. Sorting, dismantling, and safe handling, including remote-handling technologies, are an earlier stage where activity is comparatively less crowded and where European applicants are relatively strong.¹
Reuse and repurposing. Second-life applications for batteries, distinct from material recovery, are a separate and growing layer.
Design for recyclability. Battery designs that ease disassembly and recovery link circularity back to manufacturing and are an emerging cross-over area.
How AI-powered landscape and white space analysis helps
Resolving a fast-growing landscape across stages, chemistries, and geographies requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by recovery route and processing stage across varied terminology, attribution that normalizes filers to canonical entities and tracks shifting leadership, and continuous monitoring that keeps pace with a field growing far faster than average. Because circularity advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier is moving.
Where Cypris fits
Cypris runs patent landscape and white space analysis for fast-growing energy fields such as battery circularity across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by recovery route, hydrometallurgy, direct regeneration, separation, and pyrometallurgy, and by processing stage, and normalizes filers to canonical entities, so a team can resolve which routes and stages are crowded and which remain open as white space, and can track shifting leadership as new entrants rise. Semantic search across patents and scientific literature connects filings to the underlying materials and process research, which is where circularity advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
How fast is battery-recycling patenting growing? Battery-recycling patenting is growing very fast. According to the EPO and IEA, international patent families in battery circularity grew at an average of 42 percent per year from 2017 to 2023, versus 16 percent for battery manufacturing and 2 percent across all technical fields, roughly a sevenfold increase over the decade. It is now growing faster than battery patenting in general.
Who leads in battery-circularity patents? Asian applicants held 63 percent of battery-circularity patent families in 2023. China's share rose from 5 percent in 2013 to 29 percent in 2023, and Brunp, a major battery maker's recycling subsidiary, overtook established Japanese and Korean firms as the most active filer. European companies and research institutes hold roughly 20 percent, with strength in collection and pre-processing. An independent Cypris-corpus count reproduces China's roughly two-thirds share and Brunp's lead.
What technologies does the battery-recycling landscape cover? The battery-recycling landscape covers collection, sorting, and dismantling; mechanical processing; and metal recovery and cathode regeneration. Analysis of the patent record finds hydrometallurgy the most patented chemical-recovery route, ahead of pyrometallurgy, with direct recycling still comparatively nascent. Innovation concentrates on leaching efficiency, purification, and relithiation.
Why is battery circularity strategically important? Battery circularity is strategically important because it is a secondary supply of critical minerals. Around 1.2 million electric-vehicle batteries could reach end of life in 2030 and 14 million by 2040, and recycled materials could meet more than a fifth of lithium, nickel, and cobalt demand by 2040. This links recycling to supply-chain security and energy security.
Where is the white space in battery recycling? The white space in battery recycling includes direct cathode regeneration, efficient metal recovery and purification, collection and pre-processing including remote handling, reuse and repurposing for second-life applications, and design for recyclability. Metal recovery and cathode regeneration are where chemical innovation concentrates. The higher-value opportunities are in routes that improve recovery economics.
Why does battery-recycling analysis need scientific literature? Battery-recycling analysis needs scientific literature because process and materials advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams use battery-recycling patent landscape analysis? Battery-recycling patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery makers, recyclers, automotive and energy companies, materials developers, and their partners, as well as investors and policymakers. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.
How do you keep a battery-recycling landscape current? Keeping a battery-recycling landscape current requires continuous monitoring, because the field is growing far faster than average, leadership is shifting quickly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.
Endnotes
- International Energy Agency & European Patent Office (2026). Battery circularity: innovation trends for a future source of critical materials. IEA, Paris. https://www.iea.org/reports/battery-circularity
- von Delft, S., Schlehuber, S., & Hemmelder, A. (2025). Uncovering collaboration and knowledge areas in lithium-ion battery recycling. EES Batteries. https://doi.org/10.1039/d5eb00056d
- Li, Y., Guo, Y., Guan, J., Zhang, X., & Lou, X. (2022). Global trend for waste lithium-ion battery recycling from 1984 to 2021: a bibliometric analysis. Minerals, 12(12), 1514. https://doi.org/10.3390/min12121514
.avif)